Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Factor VIII inhibitor bypassing fraction
500unit) powder and 20ml solvent for solution for infusion vials (Takeda UK Ltd
B02BD03
Factor VIII inhibitor bypassing fraction
500unit
Powder and solvent for solution for infusion
Intravenous
No Controlled Drug Status
Never Valid To Prescribe As A VMP
BNF: ; GTIN: 00642621015119
OBJECT 1 FEIBA 500 U POWDER AND SOLVENT FOR SOLUTION FOR INFUSION Summary of Product Characteristics Updated 14-Jan-2016 | Shire Pharmaceuticals Limited 1. Name of the medicinal product FEIBA 500 U powder and solvent for solution for infusion 2. Qualitative and quantitative composition FEIBA is presented as powder and solvent to prepare a solution for infusion containing 200-600 mg human plasma protein with a Factor Eight Inhibitor Bypassing Activity of 500 U* per vial. The final solution has an activity of approximately 25 U/ml when reconstituted with 20 ml of Sterilised Water for Injections. FEIBA contains factors II, IX and X mainly in non-activated form as well as activated factor VII; factor VIII coagulant antigen (FVIII C:Ag) is present in a concentration of up to 0.1 U/l U FEIBA. The factors of the kallikrein-kinin system are present only in trace amounts, if at all. *A solution containing 1 unit of FEIBA shortens the activated partial thromboplastin time (aPTT) of a factor VIII inhibitor plasma to 50% of the buffer value (blank). For excipients, see 6.1. 3. Pharmaceutical form Powder and solvent for solution for infusion. The product is presented as freeze-dried powder or friable solid of white to off-white or pale green colour. 4. Clinical particulars 4.1 Therapeutic indications • Treatment of spontaneous bleeding and cover of surgical interventions in haemophilia A patients with Factor VIII inhibitors • Treatment of spontaneous bleeding and cover of surgical interventions in non haemophiliacs with acquired inhibitors to Factor VIII • Prophylaxis in haemophilia A patients with high-responding inhibitors and frequent joint bleeding 4.2 Posology and method of administration Treatment should be initiated and supervised by a physician experienced in the management of haemophilia. POSOLOGY The dosage and duration of the therapy is dependent upon the severity of the disorder, the location and extent of the bleeding and the patient's clinical condition. Dosage and frequency of administration should always Read the complete document